Cargando…

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series

Pseudoprogression is rarely mentioned after radiotherapy except for central nervous system tumors. With the widespread of immunotherapy, the incidence of pseudoprogression of thoracic tumor after radiotherapy is increasing. This study summarized the clinical features of pseudoprogression in 4 patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Yongbo, Tang, Wei, Wang, Jianyang, Wang, Zhijie, Bi, Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419187/ https://www.ncbi.nlm.nih.gov/pubmed/37576884 http://dx.doi.org/10.3389/fonc.2023.1021253

Ejemplares similares

Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review
por: Zhang, Xiaojie, et al.
Publicado: (2021)

Remission of pulmonary alveolar proteinosis after radiotherapy in a patient with comorbid small cell lung cancer
por: Xiang, Yongbo, et al.
Publicado: (2023)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
por: Jia, Wenxiao, et al.
Publicado: (2019)

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
por: Son, Christine, et al.
Publicado: (2023)

Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
por: Li, Yan, et al.
Publicado: (2021)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Pilocytic Astrocytoma Enlargement Following Irradiation: Relapse or Pseudoprogression?
por: Trunin, Yury, et al.
Publicado: (2017)

Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity
por: Tsoutsou, Pelagia G., et al.
Publicado: (2018)

Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy
por: Stauder, Michael C, et al.
Publicado: (2013)

Case Report: First Case of Consolidation Immunotherapy After Definitive Chemoradiotherapy in Mediastinal Lymph Node Metastatic Sarcomatoid Carcinoma
por: Wang, Yu, et al.
Publicado: (2022)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report
por: Tian, Aijuan, et al.
Publicado: (2023)

Functional lung imaging in thoracic tumor radiotherapy: Application and progress
por: Zhou, Pi-Xiao, et al.
Publicado: (2022)

Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases
por: Dagoglu, Nergiz, et al.
Publicado: (2019)

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
por: Yu, Siting, et al.
Publicado: (2022)

Restriction Spectrum Imaging Differentiates True Tumor Progression From Immune-Mediated Pseudoprogression: Case Report of a Patient With Glioblastoma
por: Daghighi, Shadi, et al.
Publicado: (2020)

RONC-09. PSEUDOPROGRESSION AFTER PROTON THERAPY OF PEDIATRIC SPINAL PILOCYTIC ASTROCYTOMA AND MYXOPAPILLARY EPENDYMOMA
por: McGovern, Susan, et al.
Publicado: (2020)

The confluence of radiotherapy and immunotherapy
por: Burnette, Byron, et al.
Publicado: (2012)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

F-18 Fluciclovine PET-CT Findings and Pseudoprogression on Immunotherapy
por: Poindexter, Bradley C, et al.
Publicado: (2022)

Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?
por: Khalifa, Jonathan, et al.
Publicado: (2021)

A Case Report of the Clinico-radiologic Challenges of Assessing Treatment Response after Stereotactic Radiation of Oligometastases Preceded by Immunotherapy: Pseudoprogression, Mixed Response Patterns, and Opportunities for Precision Radiation
por: Rashid, Arif S, et al.
Publicado: (2019)

Blood Biomarkers of Glioma in Response Assessment Including Pseudoprogression and Other Treatment Effects: A Systematic Review
por: Raza, Istafa J., et al.
Publicado: (2020)

Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report
por: Zhou, Jiawei, et al.
Publicado: (2023)

The role of PET/CT in radiotherapy for nasopharyngeal carcinoma
por: Li, Hongjia, et al.
Publicado: (2022)

Thoracic Wall Reconstruction after Tumor Resection
por: Harati, Kamran, et al.
Publicado: (2015)

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis
por: Yang, Zizhong, et al.
Publicado: (2021)

Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases—Implications for Intraoperative Radiotherapy after Resection
por: Herskind, Carsten, et al.
Publicado: (2017)

Dosiomics and radiomics to predict pneumonitis after thoracic stereotactic body radiotherapy and immune checkpoint inhibition
por: Kraus, Kim Melanie, et al.
Publicado: (2023)

HDAC-an important target for improving tumor radiotherapy resistance
por: Ling, Rui, et al.
Publicado: (2023)

Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

The identification of tumor antigens and immune subtypes based on the development of immunotherapies targeting head and neck squamous cell carcinomas resulting from periodontal disease
por: Fu, Yangju, et al.
Publicado: (2023)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?
por: Hörner-Rieber, Juliane, et al.
Publicado: (2021)

Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report
por: Liu, Guihong, et al.
Publicado: (2018)

The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era
por: Li, Zheng, et al.
Publicado: (2022)

Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure
por: Shi, Liyong, et al.
Publicado: (2022)

Radiotherapy: Brightness and darkness in the era of immunotherapy
por: Zhai, Danyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dpf33m9ppndlsab4goqof0cbq9